Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Investment analysts at Svb Leerink decreased their Q3 2019 earnings per share estimates for shares of Biohaven Pharmaceutical in a research note issued to investors on Monday, August 12th. Svb Leerink analyst M. Goodman now expects that the company will earn ($1.90) per share for the quarter, down from their prior estimate of ($1.57). Svb Leerink currently has a “Outperform” rating and a $67.00 target price on the stock. Svb Leerink also issued estimates for Biohaven Pharmaceutical’s Q4 2019 earnings at ($2.69) EPS, FY2019 earnings at ($8.35) EPS, FY2020 earnings at ($7.55) EPS, FY2021 earnings at ($4.15) EPS and FY2022 earnings at $1.70 EPS.
Biohaven Pharmaceutical (NYSE:BHVN) last released its earnings results on Thursday, August 8th. The company reported ($2.35) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($0.26).
NYSE BHVN opened at $39.22 on Thursday. The business has a fifty day moving average price of $42.48 and a two-hundred day moving average price of $50.30. Biohaven Pharmaceutical has a fifty-two week low of $29.17 and a fifty-two week high of $67.86. The stock has a market capitalization of $1.96 billion, a PE ratio of -6.38 and a beta of 0.24.
In other news, CFO James Engelhart purchased 2,500 shares of the company’s stock in a transaction dated Thursday, June 27th. The stock was bought at an average cost of $43.05 per share, for a total transaction of $107,625.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Vlad Coric purchased 5,000 shares of the company’s stock in a transaction dated Wednesday, June 26th. The stock was purchased at an average price of $40.22 per share, with a total value of $201,100.00. The disclosure for this purchase can be found here. Insiders bought a total of 17,500 shares of company stock valued at $712,425 over the last quarter. 23.90% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Manchester Capital Management LLC bought a new position in shares of Biohaven Pharmaceutical in the 1st quarter valued at $52,000. Tower Research Capital LLC TRC bought a new position in Biohaven Pharmaceutical during the 2nd quarter worth $65,000. Aperio Group LLC bought a new position in Biohaven Pharmaceutical during the 2nd quarter worth $71,000. Glen Harbor Capital Management LLC raised its position in Biohaven Pharmaceutical by 165.9% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after purchasing an additional 1,088 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Biohaven Pharmaceutical by 94.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,256 shares of the company’s stock worth $99,000 after purchasing an additional 1,097 shares during the last quarter. Institutional investors own 85.14% of the company’s stock.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Read More: What is the Stochastic Momentum Index (SMI)?
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.